Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 15983922)

1.

Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Liang EC, Sceats L, Bayless NL, Strauss-Albee DM, Kubo J, Grant PM, Furman D, Desai M, Katzenstein DA, Davis MM, Zolopa AR, Blish CA.

J Virol. 2014 Aug;88(15):8629-39. doi: 10.1128/JVI.01257-14. Epub 2014 May 21.

2.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102. Print 2013.

3.

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Rath BA, Olshen RA, Halpern J, Merigan TC.

Viruses. 2012 Aug;4(8):1212-34. Epub 2012 Aug 7.

4.

Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.

Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K.

Retrovirology. 2012 Jul 17;9:57. doi: 10.1186/1742-4690-9-57.

5.

HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Tang MW, Shafer RW.

Drugs. 2012 Jun 18;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. Review.

6.

Strategies to improve HIV treatment adherence in developed countries: clinical management at the individual level.

Enriquez M, McKinsey DS.

HIV AIDS (Auckl). 2011;3:45-51. doi: 10.2147/HIV.S8993. Epub 2011 May 17.

7.

Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?

Hurt CB, Eron JJ Jr, Cohen MS.

Clin Infect Dis. 2011 Dec;53(12):1265-70. doi: 10.1093/cid/cir684. Epub 2011 Oct 5. Review.

8.

Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.

Dunn DT, Goodall RL, Munderi P, Kityo C, Ranopa M, Bacheler L, Van Houtte M, Gilks C, Kaleebu P, Pillay D; DART Virology and Trial Team.

Antimicrob Agents Chemother. 2011 Oct;55(10):4575-80. doi: 10.1128/AAC.00580-11. Epub 2011 Jul 18.

9.

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM.

J Infect Dis. 2011 Apr 15;203(8):1174-81. doi: 10.1093/infdis/jiq167.

10.

Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.

Armstrong KL, Lee TH, Essex M.

Antimicrob Agents Chemother. 2011 May;55(5):2146-53. doi: 10.1128/AAC.01505-10. Epub 2011 Mar 14.

11.

International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR.

Antimicrob Agents Chemother. 2010 Apr;54(4):1520-5. doi: 10.1128/AAC.01380-09. Epub 2010 Feb 1.

12.
13.

Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1.

Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, Schneidewind A, Power KA, Toth I, Frahm N, Alter G, Brander C, Carrington M, Walker BD, Altfeld M, Heckerman D, Allen TM.

J Virol. 2009 Feb;83(4):1845-55. doi: 10.1128/JVI.01061-08. Epub 2008 Nov 26.

14.

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR.

J Virol. 2009 Feb;83(4):2038-43. doi: 10.1128/JVI.02154-08. Epub 2008 Nov 19.

15.

Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

Trivedi V, Von Lindern J, Montes-Walters M, Rojo DR, Shell EJ, Parkin N, O'Brien WA, Ferguson MR.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300. doi: 10.1089/aid.2007.0244.

16.

Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.

Borkowsky W, Yogev R, Muresan P, McFarland E, Frenkel L, Fenton T, Capparelli E, Moye J, Harding P, Ellis N, Heckman B, Kraimer J.

Vaccine. 2008 Jun 6;26(24):3086-9. doi: 10.1016/j.vaccine.2007.12.017. Epub 2008 Jan 4.

17.

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.

Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL.

AIDS. 2008 May 11;22(8):947-55. doi: 10.1097/QAD.0b013e3282ffde91.

18.

Clinical significance of human immunodeficiency virus type 1 replication fitness.

Dykes C, Demeter LM.

Clin Microbiol Rev. 2007 Oct;20(4):550-78. Review.

19.

Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Paredes R, Marconi VC, Campbell TB, Kuritzkes DR.

J Virol Methods. 2007 Dec;146(1-2):136-46. Epub 2007 Jul 26.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk